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Dimethylsulfoxide (DMSO) is a chemical com-
pound with a formula (CH3)2SO. DMSO has been 
used as a solvent in biological studies and as a vehicle 
for drug therapy for a long time [1, 2]. Since 1990, 
DMSO has been the most frequently used substance 
for cryopreservation of hematopoietic cell (HC) grafts 
[3–5]. The cryopreservation solution usually contains 
10% DMSO and 2–4% albumin or autologous plasma. 
The grade of toxicity experienced by patients when 
cryopreserved HC grafts are infused is related to the 
amount of DMSO present in the HC concentrates. 
Recently, some institutions have started using 5% 
DMSO as cryoprotectant for the autologous HC grafts 
[6, 7]. The maximum recommended daily dose of 
DMSO is 1 g/kg of the recipient body weight due to 
dose-dependent side effects. The most common side 
effects of DMSO include nausea, vomiting, diarrhea, 
rashes, bronchospasm, headache and cardiovascular 
changes [8–10]. DMSO may lead to changes in blood 
pressure (BP) and heart rate (HR). In most studies, 
increase in BP and decrease in HR were found [2, 11, 
12]. However, decrease in BP or increase in HR or no 
changes in BP and HR were reported in several stu-
dies and the results are inconsistent [9, 13]. Thus, the 
European Group for Blood and Marrow Transplantation 
(EBMT) has recently launched a multicenter study on 
monitoring of side effect of DMSO including cardiovas-
cular changes (so called “DMSO Toxicity Study”). The 
results of the study have not been published yet.
The aim of our study was to monitor BP and HR du-
ring HC graft infusions and to assess the effect of DMSO 
cryopreservation on these parameters in patients trans-
planted for a hematological disease in our transplant 
center (Department of Medicine II, Clinical Hematology, 
University Hospital Hradec Kralove, Czech Republic). 
We evaluated 153 HC graft infusions in 153 con-
secutive hematological patients. The patients con-
sisted of 80 males and 73 females with the mean age 
of 49.1 ± 12.6 years. Forty-two patients were treated 
for arterial hypertension and were well compensated 
before HC transplantation. Cryopreservation with 
DMSO was used in 133 (86.9%) grafts, 20 (13.1%) 
grafts were infused directly without cryopreservation 
(control group). One hundred and fifteen (75.2%) 
grafts were autologous and 38 (24.8%) allogeneic 
(from that 18 matched unrelated donor transplants). 
The most frequent diagnoses were multiple myeloma 
(55 patients), non-Hodgkin’s lymphoma (35 patients) 
and acute myeloid leukemia (29 patients). 
Systolic blood pressure (SBP), diastolic blood pres-
sure (DBP) and heart rate (HR) were measured imme-
diately before and after HC graft infusion. Changes (ei-
ther increase or decrease) in SBP or DBP by more than 
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10 mmHg or changes in HR by more than 10 beats/min 
were considered significant in our study.
Statistical analysis was performed with the “Sta-
tistica for Windows, Version 5.0” program. Paired two 
tailed t-tests and McNemar tests were used. The va-
lues are expressed as mean ± standard deviation (SD). 
Probability values p < 0.05 and lower were considered 
statistically significant.
The results are shown in Table 1 and Table 2. SBP 
and DBP increased significantly just after graft infu-
sions cryopreserved with DMSO. Increase in SBP by 
more than 10 mmHg was seen in 42 (31.6%) patients, 
in DBP in 31 (23.3%) patients. Moreover, the increase 
in BP and HR correlated with the increasing DMSO 
dose — changes were more pronounced in patients 
with the total DMSO dose above 0.8 g/kg of recipient 
body weight (p < 0.01, p < 0.05 respectively). In the 
control group without DMSO cryopreservation, the 
changes in SBP, DBP and HR were not significant. 
Changes in SBP, DBP and HR were not significantly 
different in patients treated for arterial hypertension 
in comparison with the other patients.
Table 1. Changes in blood pressure and heart rate during hematopoietic 
cell graft infusion with dimethylsulfoxide (n = 133)
Parameters Before HCT After HCT p
SBP (mmHg) 122.3 ± 17.9 127.7 ± 18.1 < 0.0001
DBP (mmHg) 70.9 ± 12.3 74.1 ± 12.6 < 0.01
HR (/min) 81.5 ± 13.6 81.8 ± 14.2 NS
In Table 1 and Table 2: HCT – hematopoietic cell transplantation.
Table 2. Changes in blood pressure and heart rate during hematopoietic 
cell graft infusion without dimethylsulfoxide (n = 20)
Parameters Before HCT After HCT p
SBP (mmHg) 136.3 ± 17.6 138.4 ± 15.6 NS
DBP (mmHg) 78.1 ± 9.5 76.9 ± 11.3 NS
HR (/min) 81.6 ± 23.0 81.1 ± 21.8 NS
Our results on 153 consecutive hematological pa-
tients show that only HC graft infusions cryopreserved 
with DMSO caused statistically significant increases 
in SBP and DBP. In our study, significant increases 
(by more than 10 mmHg) in SBP were found in 31.6% 
patients, in DBP in 23.3% patients. Changes in HR 
were not statistically significant. These changes were 
mostly transient and asymptomatic and did not require 
therapeutic intervention. However, they might cause 
complications, especially in patients with preexisting 
cardiovascular disease (amyloidosis with cardiac in-
volvement, chemotherapy-induced cardiomyopathy, 
coronary artery disease, cardiac arrhythmia, not 
adequately compensated arterial hypertension prior 
to HC transplantation, etc.). The patients at risk for 
cardiovascular complications should be monitored 
closely during cryopreserved HC graft infusion, e.g. 
continuous monitoring of ECG and BP. 
To reduce the side effects of cryopreservation 
agent DMSO, the amount of infused DMSO could be 
decreased by centrifugation right before the HC graft 
infusion [14]. The drawback of this procedure is a sig-
nificant loss of HC (according to our experience up to 
30%) which may result in delayed engraftment. Ano-
ther possibility is to fractionate the application of HC 
graft in more consecutive days and thereby reduce the 
total daily DMSO dose and toxicity [15].
To conclude, HC graft infusions cryopreserved with 
DMSO could cause statistically significant increases 
in SBP and DBP, without changes in HR. Patients with 
preexisting cardiovascular disease should by moni-
tored closely during HC transplantation. Alternatively, 
the amount of DMSO could be depleted before HC 
graft infusions.
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